HRP20120256T1 - Inhibitori kinaza i postupci njihove upotrebe - Google Patents
Inhibitori kinaza i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20120256T1 HRP20120256T1 HR20120256T HRP20120256T HRP20120256T1 HR P20120256 T1 HRP20120256 T1 HR P20120256T1 HR 20120256 T HR20120256 T HR 20120256T HR P20120256 T HRP20120256 T HR P20120256T HR P20120256 T1 HRP20120256 T1 HR P20120256T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- image
- pharmaceutically acceptable
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 5
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract 5
- 230000001404 mediated effect Effects 0.000 claims abstract 5
- 102000020233 phosphotransferase Human genes 0.000 claims abstract 5
- 239000000651 prodrug Substances 0.000 claims abstract 3
- 229940002612 prodrug Drugs 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- UTVBCYCHQGKWJM-UHFFFAOYSA-N 2-[5-[2-[[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]methyl]-4-fluorophenoxy]indazol-1-yl]ethyl dihydrogen phosphate Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NCC=2C(=CC=C(F)C=2)OC=2C=C3C=NN(CCOP(O)(O)=O)C3=CC=2)=CC(C(C)(C)C)=N1 UTVBCYCHQGKWJM-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- QDWJUBJKEHXSMT-UHFFFAOYSA-N boranylidynenickel Chemical compound [Ni]#B QDWJUBJKEHXSMT-UHFFFAOYSA-N 0.000 claims 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76371206P | 2006-01-31 | 2006-01-31 | |
PCT/US2007/002272 WO2007089646A1 (en) | 2006-01-31 | 2007-01-26 | Kinase inhibitors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120256T1 true HRP20120256T1 (hr) | 2012-04-30 |
Family
ID=38037453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20120256T HRP20120256T1 (hr) | 2006-01-31 | 2012-03-21 | Inhibitori kinaza i postupci njihove upotrebe |
Country Status (27)
Country | Link |
---|---|
US (2) | US8044083B2 (ru) |
EP (1) | EP1981851B1 (ru) |
JP (1) | JP5131990B2 (ru) |
KR (1) | KR101357465B1 (ru) |
CN (1) | CN101415685B (ru) |
AT (1) | ATE542800T1 (ru) |
AU (1) | AU2007210073B2 (ru) |
BR (1) | BRPI0707401B8 (ru) |
CA (1) | CA2635813C (ru) |
CY (1) | CY1112770T1 (ru) |
DK (1) | DK1981851T3 (ru) |
ES (1) | ES2379656T3 (ru) |
HK (1) | HK1123548A1 (ru) |
HR (1) | HRP20120256T1 (ru) |
IL (3) | IL192949A (ru) |
MY (1) | MY151835A (ru) |
NZ (1) | NZ570846A (ru) |
PL (1) | PL1981851T3 (ru) |
PT (1) | PT1981851E (ru) |
RS (1) | RS52298B (ru) |
RU (1) | RU2442777C2 (ru) |
SG (1) | SG175599A1 (ru) |
SI (1) | SI1981851T1 (ru) |
TW (1) | TWI388557B (ru) |
UA (1) | UA94733C2 (ru) |
WO (1) | WO2007089646A1 (ru) |
ZA (1) | ZA200806507B (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
UA94733C2 (ru) | 2006-01-31 | 2011-06-10 | Эррей Биофарма Инк. | Ингибиторы киназы и способы их использования |
WO2009015000A1 (en) * | 2007-07-25 | 2009-01-29 | Array Biopharma Inc. | Pyrazole urea derivatives used as kinase inhibitors |
EP2196461A1 (de) | 2008-12-15 | 2010-06-16 | Bayer CropScience AG | 4-Amino-1,2,3-benzoxathiazin-Derivate als Pestizide |
RU2606131C2 (ru) | 2011-05-13 | 2017-01-10 | Эррэй Биофарма Инк. | СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA |
WO2013130573A1 (en) * | 2012-03-01 | 2013-09-06 | Array Biopharma Inc. | Crystalline forms of 1- (3 -tert-butyl- 1 - p-tolyl- 1h- pyrazol- 5 -yl) -3- (5-fluoro-2- (1- ( 2 - hydroxyethyl) - indazol- 5 -yloxy) benzyl) urea hydrochloride |
US9790206B2 (en) * | 2013-02-27 | 2017-10-17 | Array Biopharma Inc. | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof |
SG10202110259QA (en) | 2017-10-05 | 2021-10-28 | Fulcrum Therapeutics Inc | Use of p38 inhibitors to reduce expression of dux4 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
RU2750702C1 (ru) * | 2017-12-13 | 2021-07-01 | Джинфлит Терапьютикс (Шанхай) Инк. | КРИСТАЛЛИЧЕСКАЯ ФОРМА И СОЛЕВАЯ ФОРМА ИНГИБИТОРА TGF-βRI И СПОСОБ ИХ ПОЛУЧЕНИЯ |
WO2023084459A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating sars-cov-2 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755332A (en) | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
JPS5998060A (ja) | 1982-11-27 | 1984-06-06 | Fujisawa Pharmaceut Co Ltd | インダゾ−ル誘導体、その製造法および農薬 |
US4571255A (en) | 1983-12-29 | 1986-02-18 | Ppg Industries, Inc. | Subsituted phenoxybenzisoxazole herbicides |
US5234942A (en) | 1984-10-19 | 1993-08-10 | Ici Americas Inc. | Heterocyclic amides and leucotriene antagonistic use thereof |
SU1545940A3 (ru) | 1984-10-19 | 1990-02-23 | Ай-Си-Ай Америказ Инк (Фирма) | Способ получени гетероциклических кислот или их солей |
GB8524157D0 (en) | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
PL265549A1 (en) | 1985-03-26 | 1988-09-01 | The method of manufacture of new heterocyclic amides | |
JPS6368568A (ja) | 1986-09-10 | 1988-03-28 | Otsuka Pharmaceut Factory Inc | p−アミノフエノ−ル誘導体 |
NZ224714A (en) | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
IE910278A1 (en) | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
US6194439B1 (en) | 1991-05-29 | 2001-02-27 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
CA2116863A1 (en) | 1992-07-03 | 1994-01-20 | Sumio Yokota | Condensed heterocyclic derivatives and herbicides |
US5587392A (en) | 1994-05-27 | 1996-12-24 | Mochida Pharmaceutical Co., Ltd. | Azolyl methyl phenyl derivatives having aromatase inhibitory activity |
KR19990064117A (ko) | 1995-10-06 | 1999-07-26 | 폴락 돈나 엘. | 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸 |
US6083949A (en) | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
CA2264798A1 (en) | 1996-09-04 | 1998-03-12 | Pfizer Inc. | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
KR100567649B1 (ko) | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
US5932570A (en) | 1996-11-08 | 1999-08-03 | Dupont Pharmaceuticals Company | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors |
EP0937067B1 (en) | 1996-11-08 | 2003-07-09 | Bristol-Myers Squibb Pharma Company | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors |
US6218386B1 (en) | 1996-11-08 | 2001-04-17 | Dupont Pharmaceuticals | A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
UA73073C2 (ru) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Замещенные 3-циан хинолины |
US5965583A (en) | 1997-04-24 | 1999-10-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory disease |
US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
CN1279682A (zh) | 1997-10-20 | 2001-01-10 | 霍夫曼-拉罗奇有限公司 | 双环激酶抑制剂 |
AU1367599A (en) | 1997-11-03 | 1999-05-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
EP1028946A1 (en) | 1997-11-04 | 2000-08-23 | Pfizer Products Inc. | Indazole bioisostere replacement of catechol in therapeutically active compounds |
SK6262000A3 (en) | 1997-11-04 | 2002-03-05 | Pfizer Prod Inc | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
US6329412B1 (en) | 1997-11-04 | 2001-12-11 | Pfizer Inc | Bisamidine compounds as antiproliferative agents |
US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
GB9820767D0 (en) | 1998-09-23 | 1998-11-18 | Cerebrus Ltd | Chemical compounds VIII |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
WO2000050425A1 (en) | 1999-02-22 | 2000-08-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polycyclo heterocyclic derivatives as antiinflammatory agents |
EP1163236B1 (en) | 1999-03-12 | 2005-11-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
DE60014603T2 (de) * | 1999-03-12 | 2006-02-16 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
JP2002540142A (ja) | 1999-03-29 | 2002-11-26 | シャイアー・バイオケム・インコーポレイテッド | 白血病の処置方法 |
AU4063600A (en) | 1999-04-05 | 2000-10-23 | Merck & Co., Inc. | A method of treating cancer |
US6355636B1 (en) | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
PT1171440E (pt) | 1999-04-21 | 2004-07-30 | Wyeth Corp | 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases |
AU772295B2 (en) | 1999-05-21 | 2004-04-22 | Scios Inc. | Indole-type derivatives as inhibitors of p38 kinase |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
WO2001004115A2 (en) | 1999-07-09 | 2001-01-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
CN1610667A (zh) | 1999-11-27 | 2005-04-27 | 同和药品工业株式会社 | 新型3-硝基吡啶衍生物和含有该衍生物的药物组合物 |
AU1899501A (en) | 1999-11-27 | 2001-06-04 | Dong Wha Pharmaceutical Industrial Co., Ltd. | Novel 3-nitropyridine derivatives and the pharmaceutical compositions containingsaid derivatives |
AU4890301A (en) | 2000-04-17 | 2001-10-30 | Dong Wha Pharmaceutical Industrial Co., Ltd. | 6-methylnicotinamide derivatives as antiviral agents |
EP1341782A2 (en) | 2000-11-20 | 2003-09-10 | Scios Inc. | Inhibitors of p38 kinase |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
TW593278B (en) | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
KR20030080087A (ko) | 2001-03-09 | 2003-10-10 | 화이자 프로덕츠 인코포레이티드 | 항염증제로서의 트리아졸로피리딘 |
JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
EA007430B1 (ru) | 2001-09-26 | 2006-10-27 | Фармация Италия С.П.А. | Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция |
JP2005506350A (ja) | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物 |
WO2003051847A1 (en) | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
ES2299689T3 (es) | 2002-02-25 | 2008-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas. |
FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
WO2003087072A1 (fr) | 2002-03-29 | 2003-10-23 | Mochida Pharmaceutical Co., Ltd. | Agent therapeutique destine a des troubles endotheliaux |
CN101423497A (zh) | 2002-07-19 | 2009-05-06 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物 |
CA2497351C (fr) | 2002-09-05 | 2012-08-21 | Aventis Pharma S.A. | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
CN1705645A (zh) | 2002-10-24 | 2005-12-07 | 默克专利有限公司 | 作为raf-激酶抑制剂的亚甲基脲衍生物 |
ES2273047T3 (es) | 2002-10-28 | 2007-05-01 | Bayer Healthcare Ag | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2004052280A2 (en) | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7521447B2 (en) | 2003-03-03 | 2009-04-21 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
GB0320244D0 (en) | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
US7129252B2 (en) | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
SE0301906D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
WO2005004818A2 (en) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
AU2004270733B2 (en) * | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
JP2007514791A (ja) | 2003-12-18 | 2007-06-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | P38mapキナーゼインヒビターであるbirb796の多形 |
MXPA06007198A (es) | 2003-12-22 | 2006-09-04 | Lilly Co Eli | Antagonistas de receptor opioide. |
WO2006122230A1 (en) | 2005-05-11 | 2006-11-16 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
UA94733C2 (ru) | 2006-01-31 | 2011-06-10 | Эррей Биофарма Инк. | Ингибиторы киназы и способы их использования |
-
2007
- 2007-01-26 UA UAA200810690A patent/UA94733C2/ru unknown
- 2007-01-26 NZ NZ570846A patent/NZ570846A/en unknown
- 2007-01-26 RS RS20120119A patent/RS52298B/en unknown
- 2007-01-26 EP EP07762713A patent/EP1981851B1/en active Active
- 2007-01-26 WO PCT/US2007/002272 patent/WO2007089646A1/en active Application Filing
- 2007-01-26 CA CA2635813A patent/CA2635813C/en active Active
- 2007-01-26 US US12/161,412 patent/US8044083B2/en active Active
- 2007-01-26 BR BRPI0707401A patent/BRPI0707401B8/pt active IP Right Grant
- 2007-01-26 JP JP2008553277A patent/JP5131990B2/ja active Active
- 2007-01-26 PT PT07762713T patent/PT1981851E/pt unknown
- 2007-01-26 AT AT07762713T patent/ATE542800T1/de active
- 2007-01-26 KR KR1020087021184A patent/KR101357465B1/ko active IP Right Grant
- 2007-01-26 SG SG2011073152A patent/SG175599A1/en unknown
- 2007-01-26 CN CN2007800120196A patent/CN101415685B/zh active Active
- 2007-01-26 AU AU2007210073A patent/AU2007210073B2/en active Active
- 2007-01-26 SI SI200730895T patent/SI1981851T1/sl unknown
- 2007-01-26 DK DK07762713.1T patent/DK1981851T3/da active
- 2007-01-26 PL PL07762713T patent/PL1981851T3/pl unknown
- 2007-01-26 ES ES07762713T patent/ES2379656T3/es active Active
- 2007-01-26 RU RU2008135332/04A patent/RU2442777C2/ru active
- 2007-01-26 MY MYPI20082836 patent/MY151835A/en unknown
- 2007-01-30 TW TW096103341A patent/TWI388557B/zh active
-
2008
- 2008-07-22 IL IL192949A patent/IL192949A/en active IP Right Grant
- 2008-07-25 ZA ZA200806507A patent/ZA200806507B/xx unknown
-
2009
- 2009-01-23 HK HK09100807.4A patent/HK1123548A1/xx unknown
-
2011
- 2011-02-03 US US13/020,578 patent/US8039639B2/en active Active
-
2012
- 2012-03-19 CY CY20121100291T patent/CY1112770T1/el unknown
- 2012-03-21 HR HR20120256T patent/HRP20120256T1/hr unknown
- 2012-05-08 IL IL219643A patent/IL219643A/en active IP Right Grant
- 2012-05-08 IL IL219644A patent/IL219644A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120256T1 (hr) | Inhibitori kinaza i postupci njihove upotrebe | |
DOP2010000309A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
NO20090075L (no) | Nye CXCR2 inhibitorer | |
CO6331450A2 (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibodores de syk o jak quinasas | |
PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
FI2291080T5 (fi) | Uusia sfingosiinifosfaattireseptorimodulaattoreita | |
AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
MX2014006210A (es) | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
UY29322A1 (es) | Inhibidores de cxcr2 | |
AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
JP2014511892A5 (ru) | ||
AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
MA37405A1 (fr) | Composés hétérocyclyle | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
CA2725933A1 (en) | Drug combinations comprising a dgat inhibitor and a ppar-agonist | |
JP2015514060A5 (ru) | ||
MX347706B (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
AR062745A1 (es) | 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa | |
AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
UY30617A1 (es) | Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones | |
BR112014023384A8 (pt) | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. | |
JP2009525330A5 (ru) |